- Home
- ZTEK vs NSPR Comparison
ZTEK vs NSPR Comparison
Compare ZTEK & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | NSPR |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 72.1M |
| IPO Year | 2022 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | NSPR |
|---|---|---|
| Price | $0.50 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 79.6K | 43.7K |
| Earning Date | 02-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $1.28 |
| 52 Week High | $1.84 | $2.93 |
Technical Indicators
Market Signals| Indicator | ZTEK | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 32.35 |
| Support Level | N/A | $1.28 |
| Resistance Level | $0.57 | $2.50 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 34.32 | 15.82 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About NSPR InspireMD Inc.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.